Home » Stocks » OYST

Oyster Point Pharma, Inc. (OYST)

Stock Price: $14.25 USD -0.96 (-6.31%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 370.18M
Revenue (ttm) n/a
Net Income (ttm) -72.91M
Shares Out 25.98M
EPS (ttm) -2.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $14.25
Previous Close $15.21
Change ($) -0.96
Change (%) -6.31%
Day's Open 14.93
Day's Range 14.23 - 15.21
Day's Volume 156,883
52-Week Range 14.23 - 28.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PRINCETON, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced preclinical data in non-human primates and in vitro models evaluating OC-01 (varenicline) nas...

1 month ago - GlobeNewsWire

PRINCETON, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray followin...

1 month ago - GlobeNewsWire

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

1 month ago - GlobeNewsWire

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

1 month ago - GlobeNewsWire

PRINCETON, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

1 month ago - GlobeNewsWire

Oyster Point Pharma Inc (NASDAQ: OYST) has announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene Therapy and proof-of-concept in vivo study results from its firs...

1 month ago - Benzinga

PRINCETON, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

1 month ago - GlobeNewsWire

PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a clinical-stage biopharmaceutical company focused on the discovery...

2 months ago - GlobeNewsWire

OYST, CDAY, GWPH, HRTG, and NATI have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2021

Other stocks mentioned: CDAY, GWPH, HRTG, NATI
2 months ago - Zacks Investment Research

PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of firs...

3 months ago - GlobeNewsWire

George Eliades joins the Board of Directors George Eliades joins the Board of Directors

3 months ago - GlobeNewsWire

PRINCETON, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fi...

4 months ago - GlobeNewsWire

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

5 months ago - GlobeNewsWire

PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a clinical-stage biopharmaceutical company focused on the discover...

5 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET

5 months ago - GlobeNewsWire

PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

7 months ago - GlobeNewsWire

The NDA submission is based on efficacy and safety results from a comprehensive clinical trial program conducted in patients with a broad range of dry eye disease. The NDA submission is based on efficac...

7 months ago - GlobeNewsWire

Industry veterans in ophthalmology will lead and expand the company's R&D and clinical efforts Industry veterans in ophthalmology will lead and expand the company's R&D and clinical efforts

7 months ago - GlobeNewsWire

Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021 Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021

8 months ago - GlobeNewsWire

PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

8 months ago - GlobeNewsWire

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Conference Call and Webcast Scheduled for November 5, 2020, 4:30 pm ET Conference Call and Webcast Scheduled for November 5, 2020, 4:30 pm ET

9 months ago - GlobeNewsWire

Ali Behbahani, M.D. takes on role of Chairperson of the Board

9 months ago - GlobeNewsWire

PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

10 months ago - GlobeNewsWire

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

PRINCETON, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

11 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for August 5, 2020, 8:30 am ET Conference Call and Webcast Scheduled for August 5, 2020, 8:30 am ET

1 year ago - GlobeNewsWire

Oyster Point (OYST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ph...

1 year ago - GlobeNewsWire

PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ph...

1 year ago - GlobeNewsWire

PRINCETON, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ph...

1 year ago - GlobeNewsWire

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal spra...

1 year ago - GlobeNewsWire

ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020

1 year ago - GlobeNewsWire

Oyster Point Pharma: This Is An Attractive Dry Eye Disease Player For 2020

1 year ago - Seeking Alpha

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

PRINCETON, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

1 year ago - GlobeNewsWire

About OYST

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeto... [Read more...]

Industry
Biotechnology
IPO Date
Oct 31, 2019
Stock Exchange
NASDAQ
Ticker Symbol
OYST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for OYST stock is "Buy." The 12-month stock price forecast is 64.00, which is an increase of 349.12% from the latest price.

Price Target
$64.00
(349.12% upside)
Analyst Consensus: Buy